PubMed HealthSearch

PubMed · 9111296

Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors.

Abstract

The efficiency of the drug discovery process can be significantly improved using design techniques to maximize the diversity of structure databases or combinatorial libraries. Here, several physicochemical descriptors were investigated to quantify molecular diversity. Based on the 2D or 3D topological similarity of molecules, the relationship between physicochemical metrics and biological activity was studied to find valid descriptors. Several compounds were selected using those descriptors from a database containing diverse templates and 55 biological classes. It was evaluated whether the obtained subsets represent all biological properties and structural variations of the original database. In addition, hierarchical cluster analyses were used to group molecules from the parent database, which should have similar biological properties. Using various sets of structurally similar molecules, it was possible to derive quantitative measures for compound similarities in relation to biological properties. A similarity radius for 2D fingerprints and molecular steric fields was estimated; compounds within this radius of another molecule were shown to have comparable biological properties. This study demonstrates that 2D fingerprints alone or in combination with other metrics as the primary descriptor allow to handle global diversity. In addition, standard atom-pair descriptors or molecular steric fields can be used to correlate structural diversity with biological activity. Hence, the latter two descriptors can be classified as secondary descriptors useful for analog library design, while 2D fingerprints are applicable to design a general library for lead discovery. Based on these findings, an optimally diverse subset containing only 38% of the entire IC93 database was generated using 2D fingerprints. Here no structure is more similar than 0.85 to any other (Tanimoto coefficient), but all biological classes were selected. This reduction of redundancy led to a child database with the same physicochemical diversity space, which contains the same information as the original database.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Matter. 1997-04-11. Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors.. https://doi.org/10.1021/jm960352%2B

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

BACKGROUND: Previous studies have reported an increased risk of cancer with calcium-channel blockers in man. Other work in animals suggests that inhibitors of angiotensin-I-converting enzyme (ACE) protect against cancer. We aimed to assess the risk of cancer in hypertensive patients receiving ACE inhibitors or other antihypertensive drugs. METHODS: Our retrospective cohort study was based on the records of 5207 patients who attended the Glasgow Blood Pressure Clinic between Jan 1, 1980, and Dec 31, 1995. The patients' records are linked with the Registrar General Scotland and the West of Scotland Cancer Registry. FINDINGS: Compared with the West of Scotland controls, the relative risks of incident and fatal cancer among the 1559 patients receiving ACE inhibitors were 0.72 (95% CI 0.55-0.92) and 0.65 (0.44-0.93). Among the 3648 patients receiving antihypertensive drugs other than ACE inhibitors (calcium-channel blockers 1416, diuretics 2099, beta-blockers 2681), the corresponding relative risks were 110 (0.97-1.22) and 1.03 (0.87-1.20). The relative risk of cancer was lowest in women on ACE inhibitors: 0.63 (0.41-0.93) for incident cancer; 0.48 (0.23-0.88) for fatal cancer; and 0.37 (0.12-0.87) for female-specific cancers. The reduced relative risk of cancer in patients on ACE inhibitors was greatest with follow-up of longer than 3 years. Calcium-channel blockers, diuretics, and beta-blockers had no apparent effect on risk of cancer. INTERPRETATION: Long-term use of ACE inhibitors may protect against cancer. The status of this finding is more that of hypothesis generation than of hypothesis testing; randomised controlled trials are needed.

Angiotensin-Converting Enzyme Inhibitors